BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  Merck’s Keytruda Nets Another Win in Melanoma

  The approval of Keytruda also now includes stage III melanoma following complete resection for pediatric patients 12 years and up.

  December 6, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  New Mesoblast Data Offers Hope for High-Risk Heart Patients

  The latest updates from Mesoblast Limited’s Phase III trial on rexlemestrocel-L show that the drug provides the highest benefit when used in patients with certain types of chronic heart failure.

  December 6, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Pharm Country

  COVID-19: Omicron May be Mild; J&J Data Support Mix & Match Boosting

  Data is still coming in from South Africa and other regions about the new Omicron variant of COVID-19. Early analysis suggests it causes less severe disease than other variants.

  December 6, 2021

   · 

  5 min read

   · 

  Mark Terry
• 

  Drug Development

  Trials Show Hope on the Horizon for Dravet Syndrome, Glioblastoma

  An investigational drug for Dravet syndrome is showing promise in treating the progressive form of genetic epilepsy.

  December 6, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Aeglea Rare Disease Drug Dazzles in Biomarker Data, Misses on Clinical Benefit

  Austin, Texas-based Aeglea Biotherapeutics reported what initially appears to be positive outcomes for its Phase III PEACE trial of pegzilarginase in Arginase 1 Deficiency (ARG1-D).

  December 6, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  FDA

  New FDA Safety Warning Potentially Bad News for JAK Market

  The regulatory agency just placed new safety warnings on that drug class, which will impact AbbVie’s Rinvoq (upadacitinib), a drug the company has seen as a successor to its revenue-driving Humira.

  December 6, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  NanoMosaic Scores Nearly $41 Million to Overcome Proteomic Analysis Bottleneck

  NanoMosaic plans to use the funds raised to continue building its commercial infrastructure, developing its applications, and advancing diagnostic collaborative development programs.

  December 6, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Adicet Bio’s Off-the-Shelf Drug Showing Positive Early Signals

  ADI-001 generated positive early responses from three of four evaluable participants, two of whom achieved complete responses while one had a partial response that researchers logged as “near complete.”

  December 6, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Biohaven Migraine Drug Demonstrates Rapid Recovery in Pivotal Trial

  The company said the study demonstrated broad efficacy, showing statistically significant superiority to placebo over a total of 15 prespecified primary and secondary outcome measures.

  December 6, 2021

   · 

  2 min read

   · 

  Alvin Clavines
• 

  Drug Development

  Engrafting Bacteria for Therapeutic Advantage in Kidney-Related Diseases

  Proof of concept for the Genetically Engineered Microbial Medicines (GEMM) platform came in a recent first-in-human, Phase I trial.

  December 6, 2021

   · 

  4 min read

   · 

  Gail Dutton